SENECA THERAPEUTICS
Seneca is a biotechnology company that focuses on developing novel oncolytic immunotherapeutics and derivatives as cancer therapeutics, cancer vaccines, and vaccines for the treatment of cancer. This oncolytic immunotherapeutic is called Seneca Valley Virus (SVV) which eliminates tumor cells in which it can replicate. Seneca Therapeutics is headquartered in Blue Bell, Pennsylvania.
SENECA THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Life Science Pharmaceutical
Founded:
2018-01-01
Address:
Blue Bell, Pennsylvania, United States
Country:
United States
Website Url:
http://www.senecatherapeutics.com
Status:
Active
Contact:
484-883-9725
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Microsoft Exchange Online Organization Schema Microsoft Azure DNS
Similar Organizations
Biopep Solutions
Biopep Solutions is a biotechnology company that discovers and develops therapeutic products for the treatment of cancer and other diseases.
Netnoids Rx Laboratories
Netnoids Rx Laboratories uses patient-derived organoid model systems to help find a cure for rare cancers.
SciSafe
SciSafe is a biotechnology company that offers dedicated pharmaceutical and biological specimen storage in its state of the art facility.
Current Employees Featured
Founder
Investors List
Mid Atlantic Bio Angels
Mid Atlantic Bio Angels investment in Venture Round - Seneca Therapeutics
Broad Street Angels
Broad Street Angels investment in Venture Round - Seneca Therapeutics
Official Site Inspections
http://www.senecatherapeutics.com Semrush global rank: 6.57 M Semrush visits lastest month: 954
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Seneca Therapeutics" on Search Engine
Seneca Therapeutics - Crunchbase Company Profile
About. Seneca is a biotechnology company that focuses on developing novel oncolytic immunotherapeutics for the treatment of cancer. Blue Bell, Pennsylvania, United โฆSee details»
Seneca Therapeutics Company Profile 2024: Valuation, โฆ
Information on valuation, funding, cap tables, investors, and executives for Seneca Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Seneca Therapeutics, Inc. | LinkedIn
8. Seneca Therapeutics, Inc. | 385 followers on LinkedIn. Seneca Therapeutics is developing a novel cancer therapy (oncolytic immunotherapeutic) for patients with solid โฆSee details»
Seneca Therapeutics, Inc. Announces Launch of a Novel โฆ
Sep 21, 2021 PHILADELPHIA-- ( BUSINESS WIRE )--Seneca Therapeutics, Inc. (โSTIโ), a clinical-stage biopharmaceutical company dedicated to the development of targeted โฆSee details»
Seneca Therapeutics, Inc. Receives Positive Feedback โฆ
Sep 14, 2020 PHILADELPHIA-- ( BUSINESS WIRE )-- Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic โฆSee details»
Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics โฆ
Dec 11, 2023 Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV and further the development of SVV-001 in several upcoming clinical โฆSee details»
Seneca Therapeutics | VentureRadar
Location: USA. Founded in 2020. Develops oncolytic immunotherapeutics for treating solid cancers, with a lead asset, SVV, that selectively replicates in certain human tumor โฆSee details»
Seneca Therapeutics - Funding, Financials, Valuation & Investors
Funding. Seneca Therapeutics has raised a total of. $7.7M. in funding over 3 rounds. Their latest funding was raised on Jan 5, 2023 from a Convertible Note round. Seneca โฆSee details»
Seneca Therapeutics - Contacts, Employees, Board Members, โฆ
Seneca is a biotechnology company that focuses on developing novel oncolytic immunotherapeutics for the treatment of cancer.See details»
Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 โฆ
Oct 3, 2022 PHILADELPHIA-- ( BUSINESS WIRE )--Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel โฆSee details»
Seneca Therapeutics Expands Product Pipeline Adding Six New โฆ
Feb 8, 2021 PHILADELPHIA-- ( BUSINESS WIRE )--Seneca Therapeutics, Inc. (โSTIโ), a clinical-stage biopharmaceutical company dedicated to the development of targeted โฆSee details»
SVV 001 - AdisInsight
SVV 001 (nonpathogenic Seneca Valley Virus isolate 001) is an oncolytic virus immunotherapy, being developed by Seneca Therapeutics, for the treatment of.See details»
SVV-058 - Drug Targets, Indications, Patents - Synapse
4 days ago Seneca Therapeutics, Inc. Startup. Inactive Organization - Drug Highest Phase Preclinical. First Approval Date - Regulation - Related. 100 Clinical Results โฆSee details»
Home โ Seneca Therapeutics Therapeutics
We believe a cure for cancer is within our lifetime and we are working with urgency to see this promising possibility become a reality. learn more ๏ปฟ๏ปฟSee details»
Seneca Therapeutics - Crunchbase
Seneca is a biotechnology company that focuses on developing novel oncolytic immunotherapeutics for the treatment of cancer.See details»
Honours Bachelor of Therapeutic Recreation - Seneca โฆ
As a student of this program, you will gain essential knowledge and expertise in the core foundational theories and concepts within therapeutic recreation, as well as various โฆSee details»
Presentation โ Seneca Therapeutics Therapeutics
Seneca Therapeutics Corporate Presentation . Subscribe. Sign up with your email address to receive news and updates. Email Address. Sign Up. Thank you! Back to TopSee details»
Britain refuses to sign global vaccine treaty that would force it to ...
May 8, 2024 This would include therapeutics, PPE and vaccines. The WHO document states the UN-run agency would get โreal-time accessโ to 10 per cent of these products โฆSee details»
Seneca Therapeutics - Tech Stack, Apps, Patents & Trademarks
Seneca is a biotechnology company that focuses on developing novel oncolytic immunotherapeutics for the treatment of cancer.See details»